Regeneron Pharmaceuticals

“ The global Artificial Intelligence for Financial market research explores the present competitive development of the market.. Using data obtained from trustworthy sources and proven analytical methodologies, the essay examines the current economic state of the Artificial Intelligence for Financial company in both domestic and international markets Request a sample report @ https://www.orbisresearch.com/reports/index/global-artificial-intelligence-for-financial-production-demand-and-key-producers-2022-2028 The…

BioNTech SE Acquisition aims to strengthen BioNTech’s pioneering position in the field of AI-powered drug discovery, design and development InstaDeep to operate as London based subsidiary of BioNTech and will be the centerpiece of its growing portfolio of initiatives around artificial intelligence and machine learning Approximately 290 highly skilled professionals and a global…

Healthcare innovation in drug development intersects with a few critical trends: the rise of artificial intelligence (AI) applications in healthcare—particularly machine learning (ML) and predictive analytics; the need to reduce the costs associated with drug development; and the need to improve the performance of these treatments. A discussion paper from the U.S. Food and…

It's just starting to dip its toes into the biopharma waters.

It's just starting to dip its toes into the biopharma waters.

Fagan Associates Inc. increased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 2.2% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,138 shares of the biopharmaceutical company's stock after buying an additional 178 shares…

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) is set to release its earnings data before the market opens on Thursday, August 3rd. Analysts expect Regeneron Pharmaceuticals to post earnings of $8.66 per share for the quarter. Persons that are interested in registering for the company's earnings conference call can do so using this link. …

Regeneron Pharmaceuticals’ stock has witnessed an 8.3% decline over the past three months, dampening investor excitement. However, looking at the company’s long-term financial performance, there are promising aspects to consider, particularly the Return on Equity (ROE). ROE is a measure of how effectively a company is growing its value and managing investors’ money. It reflects…

Biomedical research AI platform Causaly has raised $60 million in Series B funding to accelerate its AI-powered preclinical discovery efforts. The company, founded in 2018, has developed a unique AI platform that serves as a catalyst for life sciences research organizations. The process of developing new drugs typically takes over a decade and involves extensive…

After Regeneron’s high-dose Eylea received a surprising FDA snub, the FDA disclosed cleaning and procedural issues at Catalent, the manufacturer linked with the rejection. | Regeneron's recent FDA rejection of the high-dose Eylea was attributed to manufacturing issues at Catalent's Indiana site, the company confirmed. The observations at the site have now been disclosed,…

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) - Analysts at Cantor Fitzgerald issued their FY2024 EPS estimates for Regeneron Pharmaceuticals in a research note issued to investors on Tuesday, July 11th. Cantor Fitzgerald analyst O. Brayer expects that the biopharmaceutical company will post earnings of $33.17 per share for the year. The consensus estimate for…

Artificial intelligence has been a big theme in the world of health and medical research, and specifically in the area of drug discovery. Today, another hopeful in the space is announcing a funding round to expand its own contribution to the field. Causaly, a London startup that has built an AI platform to help researchers…